B2B: Prostate Cancer-Reference-Cited by-同舟云学术

B2B: Prostate Cancer

Published:2021-07-16 Issue:Supplement 1 Volume:2 Page:S30-S50
ISSN:2563-6499
Container-title:Proceedings from the SIU B2B Uro-Oncology: GU Cancers Triad Virtual Meeting May 21–22, 2021
language:
Short-container-title:

Author:

Loeb Stacy,Black Peter C.,Wyatt Alexander W.,Nyame Yaw A.,Shore Neal,Tilki Derya,Castro Elena,Cooperberg Matthew,Giri Veda,Ribal Maria J.,Lughezzani Giovanni,Sánchez-Salas Rafael,Moore Caroline M.,Rastinehad Art,Kerkmeijer Linda,Ahmed Hashim U.,Akamatsu Shusuke,de la Taille Alexandre,Gleave Martin,Tanguay Simon

Publisher

Societe Internationale dUrologie

Reference137 articles.

1. Vandekerkhove G, Wyatt A. Circulating tumour DNA as a biomarker source in metastatic prostate cancer. Société Internationale d’Urologie Journal. 2020;1(1):39-48.

2. 2. Annala M, Vandekerkhove G, Khalaf D, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discovery. 2018;8(4):444-457. doi:10.1158/2159-8290.CD-17-0937

3. 3. Annala M, Fu S, Bacon JVW, et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Annals of Oncology. 2021;32(7):896-905. doi:10.1016/j.annonc.2021.03.205

4. 4. Vandekerkhove G, Struss WJ, Annala M, et al. Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer. European Urology. 2019;75(4):667-675. doi:10.1016/j.eururo.2018.12.042

5. 5. PROstate Cancer TReatment optimization via analysis of circulating tumour DNA. Accessed June 6, 2021. https://clinicaltrials.gov/ct2/show/NCT04015622